Given the head-to-head data from the SPIRIT trial, Humira maker AbbVie may face even further challenges in trying to maintain its sales as newer products like ixekizumab advance in such therapeutic areas as psoriatic arthritis (PsA).
Eli Lilly and Company have announced findings from the phase 3b/4 SPIRIT trial, a head-to-head comparison of ixekizumab (Taltz) and adalimumab (Humira) in patients with psoriatic arthritis (PsA).
The study met its primary end point of superiority of ixekizumab to adalimumab in the proportion of patients who achieved American College of Rheumatology criteria for 50% improvement (ACR50) and complete skin clearance as measured by the Psoriasis Area and Severity Index (PASI 100).
The assessor-blinded, randomized controlled trial in 566 patients (234 of whom were randomized to receive ixekizumab and 231 of whom were randomized to receive adalimumab) was the first head-to-head study to use on-label dosing for both agents and to allow for concomitant treatment with conventional disease-modifying antirheumatic drugs. Patients received their assigned treatment for 52 weeks, with the primary analysis taking place at week 24.
At week 24, the proportion of patients who had achieved both ACR50 and PASI 100 was 36% in the ixekizumab arm versus 28% in the adalimumab arm (P <.05). The trial also met key secondary end points, including noninferiority of ixekizumab to adalimumab in the percentage of patients achieving ACR50 and superiority to adalimumab in the percentage of patients achieving PASI 100.
The safety profile of ixekizumab was also consistent with previously reported data, with the most commonly reported adverse events being infections, injection-site reactions, hypersensitivity reactions, and cerebrocardiovascular events. No new safety signals were detected.
In a statement, Philip Mease, MD, Swedish Medical Center, Providence St. Joseph Health, and the University of Washington, said that “head-to-head data like these are significant and help inform treatment decisions. This study underscores that Taltz is an important option for healthcare providers to consider for their patients."
These results showing that ixekizumab has outperformed the once-dominant Humira come as biosimilars of adalimumab have gained significant ground in the European context. Since their arrival in the marketplace in October 2018, biosimilar adalimumab options have secured a majority of the market share in a number of nations through national tenders.
Given the head-to-head data from the SPIRIT trial, Humira maker AbbVie may face even further challenges in trying to maintain its sales as newer products like ixekizumab advance in such therapeutic areas as PsA.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
May 4th 2024A review article summarizes the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.